BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ; Design of Treatment Trials Committee. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51. [PMID: 16678567 DOI: 10.1053/j.gastro.2005.11.058] [Cited by in Crossref: 232] [Cited by in F6Publishing: 250] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Aslam H, Khan A, Qazi NG, Ali F, Hassan SSU, Bungau S. Pharmacological basis of bergapten in gastrointestinal diseases focusing on H+/K+ ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1005154] [Reference Citation Analysis]
2 Shin SY, Park S, Moon JM, Kim K, Kim JW, Chun J, Lee TH, Choi CH; Microbiome Research Group of the Korean Society for Neurogastroenterology and Motility. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. J Neurogastroenterol Motil 2022;28:642-54. [PMID: 36250371 DOI: 10.5056/jnm21202] [Reference Citation Analysis]
3 Browne PD, de Bruijn CMA, Speksnijder EM, Hollander BD, van Wering HM, Wessels MMS, Groeneweg M, Goede J, Frankenhuis C, Tromp E, Benninga MA, Vlieger AM. Skills or Pills: Randomized Trial Comparing Hypnotherapy to Medical Treatment in Children With Functional Nausea. Clin Gastroenterol Hepatol 2022;20:1847-1856.e6. [PMID: 34718171 DOI: 10.1016/j.cgh.2021.10.029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 van der Schoot A, Drysdale C, Whelan K, Dimidi E. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Clin Nutr 2022;116:953-69. [PMID: 35816465 DOI: 10.1093/ajcn/nqac184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chuah KH, Cheong SY, Lim SZ, Mahadeva S. Functional dyspepsia leads to more healthcare utilization in secondary care compared with other functional gastrointestinal disorders. J Dig Dis 2022;23:111-7. [PMID: 35050547 DOI: 10.1111/1751-2980.13082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Radziwon CD, Quigley BM, Vargovich AM, Krasner SS, Gudleski GD, Mason SR, Borden AB, Lackner JM. Do I really have to do my homework? The role of homework compliance in cognitive behavioral therapy for irritable bowel syndrome. Behaviour Research and Therapy 2022. [DOI: 10.1016/j.brat.2022.104063] [Reference Citation Analysis]
7 Shen (申江红) J, Ye (叶永铭) Y, Zhu (朱可欣) K, Li (李珊珊) S. Acupuncture for diarrhea-predominant irritable bowel syndrome: A randomized control study. World Journal of Acupuncture - Moxibustion 2022. [DOI: 10.1016/j.wjam.2022.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Miwa H, Nagahara A, Asakawa A, Arai M, Oshima T, Kasugai K, Kamada K, Suzuki H, Tanaka F, Tominaga K, Futagami S, Hojo M, Mihara H, Higuchi K, Kusano M, Arisawa T, Kato M, Joh T, Mochida S, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. [DOI: 10.1007/s00535-021-01843-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
9 Lackner JM, Gudleski GD, Radziwon CD, Krasner SS, Naliboff BD, Vargovich AM, Borden AB, Mayer EA. Cognitive flexibility improves in cognitive behavior therapy for irritable bowel syndrome but not nonspecific education/support. Behaviour Research and Therapy 2022. [DOI: 10.1016/j.brat.2022.104033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S, Freitag M, Frieling T, Gebhard M, Goebel-Stengel M, Häuser W, Holtmann G, Keller J, Kreis ME, Kruis W, Langhorst J, Jansen PL, Madisch A, Mönnikes H, Müller-Lissner S, Niesler B, Pehl C, Pohl D, Raithel M, Röhrig-Herzog G, Schemann M, Schmiedel S, Schwille-Kiuntke J, Storr M, Preiß JC, Andus T, Buderus S, Ehlert U, Engel M, Enninger A, Fischbach W, Gillessen A, Gschossmann J, Gundling F, Haag S, Helwig U, Hollerbach S, Karaus M, Katschinski M, Krammer H, Kuhlbusch-Zicklam R, Matthes H, Menge D, Miehlke S, Posovszky MC, Schaefert R, Schmidt-Choudhury A, Schwandner O, Schweinlin A, Seidl H, Stengel A, Tesarz J, van der Voort I, Voderholzer W, von Boyen G, von Schönfeld J, Wedel T; Collaborators:., in Zusammenarbeit mit:., Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)., Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)., Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)., Deutsche Gesellschaft für Ernährungsmedizin (DGEM)., Deutsche Gesellschaft für Geriatrie (DGG)., Deutsche Gesellschaft für Innere Medizin (DGIM)., Deutsche Gesellschaft für Naturheilkunde (DGNHK)., Deutsche Gesellschaft für Pathologie und Bundesverband deutscher Pathologen e. V. (DGP/BDP)., Deutsche Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM)., Deutsche Gesellschaft für Verhaltensmedizin und Verhaltensmodifikation (DGVM)., Deutsche Schmerzgesellschaft e. V., Deutsches Kollegium für Psychosomatische Medizin (DKPM), Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG)., Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)., Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ)., Swiss Society of Neurogastroenterology and Motility (SwissNGM)., Informationsforum für Patient:innen mit Magen-Darm-Erkrankungen (MAGDA). Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016. Z Gastroenterol 2021;59:1323-415. [PMID: 34891206 DOI: 10.1055/a-1591-4794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Becheanu CA, Smădeanu RE, Ţincu IF. Effect of a Symbiotic Mixture on Fecal Microbiota in Pediatric Patients Suffering of Functional Abdominal Pain Disorders. Processes 2021;9:2157. [DOI: 10.3390/pr9122157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ho RST, Ho FF, Adams J, Cramer H, Leung B, Ward L, Zhang Y, Chung VCH. Patients' perceptions on non-specific effects of acupuncture: Qualitative comparison between responders and non-responders. Integr Med Res 2022;11:100771. [PMID: 34660196 DOI: 10.1016/j.imr.2021.100771] [Reference Citation Analysis]
13 Dunlap LJ, Jaccard J, Lackner JM. Minimal-Contact Versus Standard Cognitive Behavioral Therapy for Irritable Bowel Syndrome: Cost-Effectiveness Results of a Multisite Trial. Ann Behav Med 2021;55:981-93. [PMID: 33821928 DOI: 10.1093/abm/kaaa119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Cassar GE, Youssef GJ, Knowles S, Moulding R, Austin DW. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs 2020;43:E102-22. [PMID: 32487960 DOI: 10.1097/SGA.0000000000000530] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
15 Zhang X, Gu H, Shi Z, Li X. Effects of intradermal needle therapy plus pinaverium bromide on gastrointestinal hormone levels in irritable bowel syndrome-diarrhea patients. J Acupunct Tuina Sci 2020;18:431-7. [DOI: 10.1007/s11726-020-1211-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Hoekman DR, Vlieger AM, Stokkers PC, Mahhmod N, Rietdijk S, de Boer NK, de Meij TG, Frankenhuis C, D'Haens GR, Benninga MA. Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial. J Crohns Colitis 2021;15:1106-13. [PMID: 33245332 DOI: 10.1093/ecco-jcc/jjaa241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Basnayake C, Kamm MA, Stanley A, Wilson-o'brien A, Burrell K, Lees-trinca I, Khera A, Kantidakis J, Wong O, Fox K, Talley NJ, Liew D, Salzberg MR, Thompson AJ. Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. The Lancet Gastroenterology & Hepatology 2020;5:890-9. [DOI: 10.1016/s2468-1253(20)30215-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
18 Wang Y, Hou YQ, Yang JW, Wang LQ, Shao JK, Zou X, Yang NN, Huang J, Liu CZ. Acupuncture of different treatment frequency in postprandial distress syndrome: A pilot randomized clinical trial. Neurogastroenterol Motil 2020;32:e13812. [PMID: 32048788 DOI: 10.1111/nmo.13812] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Jean-michel M, Olivier P, Souad R S, Stéphane S. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future objectives. Arch Clin Gastroenterol 2020;6:031-035. [DOI: 10.17352/2455-2283.000075] [Reference Citation Analysis]
20 Sadrin S, Sennoune S, Gout B, Marque S, Moreau J, Zinoune K, Grillasca JP, Pons O, Maixent JM. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis 2020;52:534-40. [PMID: 31952938 DOI: 10.1016/j.dld.2019.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ansari SF, Khan AU, Qazi NG, Shah FA, Naeem K. In Vivo, Proteomic, and In Silico Investigation of Sapodilla for Therapeutic Potential in Gastrointestinal Disorders. Biomed Res Int 2019;2019:4921086. [PMID: 31886219 DOI: 10.1155/2019/4921086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
22 Chung VC, Wong CH, Wu IX, Ching JY, Cheung WK, Yip BH, Chan KL, Cheong PK, Wu JC. Electroacupuncture plus on-demand gastrocaine for refractory functional dyspepsia: Pragmatic randomized trial. J Gastroenterol Hepatol 2019;34:2077-85. [PMID: 31117149 DOI: 10.1111/jgh.14737] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
23 Basnayake C, Kamm MA, Salzberg M, Khera A, Liew D, Burrell K, Wilson-O'Brien A, Stanley A, Talley NJ, Thompson AJ. Defining Optimal Care for Functional Gut Disorders - Multi-Disciplinary Versus Standard Care: A Randomized Controlled Trial Protocol. Contemp Clin Trials 2019;84:105828. [PMID: 31437539 DOI: 10.1016/j.cct.2019.105828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Liang D, Longgui N, Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. Medicine (Baltimore) 2019;98:e16068. [PMID: 31277101 DOI: 10.1097/MD.0000000000016068] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
25 Lackner JM, Jaccard J; IBS Outcome Study Research Group. Factors Associated With Efficacy of Cognitive Behavior Therapy vs Education for Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2019;17:1500-1508.e3. [PMID: 30613000 DOI: 10.1016/j.cgh.2018.10.033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
26 Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, Castellaneta S, Barone M, Indrio F, Gobbetti M, De Angelis M. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. J Clin Gastroenterol 2019;53:e117-25. [PMID: 29688915 DOI: 10.1097/MCG.0000000000001023] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 17.0] [Reference Citation Analysis]
27 van Zanten SV. Functional Dyspepsia. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch8] [Reference Citation Analysis]
28 Lackner JM, Jaccard J, Radziwon CD, Firth RS, Gudleski GD, Hamilton F, Katz LA, Keefer L, Krasner SS, Ma CX, Sitrin MD, Brenner DM. Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up. Am J Gastroenterol 2019;114:330-8. [PMID: 30429592 DOI: 10.1038/s41395-018-0396-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
29 Flik CE, Laan W, Zuithoff NPA, van Rood YR, Smout AJPM, Weusten BLAM, Whorwell PJ, de Wit NJ. Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial. The Lancet Gastroenterology & Hepatology 2019;4:20-31. [DOI: 10.1016/s2468-1253(18)30310-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
30 Browne PD, Nagelkerke SCJ, van Etten-jamaludin FS, Benninga MA, Tabbers MM. Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review. Expert Review of Clinical Pharmacology 2018;11:1195-208. [DOI: 10.1080/17512433.2018.1540298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
31 Hod K, Dekel R, Aviv Cohen N, Sperber A, Ron Y, Boaz M, Berliner S, Maharshak N. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2018;30:e13456. [PMID: 30136337 DOI: 10.1111/nmo.13456] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
32 Lackner J, Jaccard J. Reply. Gastroenterology 2018;155:2024-5. [PMID: 30419207 DOI: 10.1053/j.gastro.2018.11.013] [Reference Citation Analysis]
33 Yiannakou Y, Agrawal A, Allen PB, Arebi N, Brown SR, Eugenicos MP, Farmer AD, McLain-Smith S, McLaughlin J, Sanders DS, Lawrance D, Emmanuel A. UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. Therap Adv Gastroenterol 2018;11:1756284818798791. [PMID: 30302125 DOI: 10.1177/1756284818798791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
34 Goldenberg JZ, Steel A, Day A, Yap C, Bradley R, Cooley K. Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics. Integr Med Res 2018;7:279-86. [PMID: 30271717 DOI: 10.1016/j.imr.2018.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 Yoon JY, Cha JM, Oh JK, Tan PL, Kim SH, Kwak MS, Jeon JW, Shin HP. Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study. Dig Dis Sci 2018;63:2754-64. [PMID: 29876777 DOI: 10.1007/s10620-018-5139-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
36 Ko SJ, Park JW, Lee JH, Lee JE, Ha NY, Nam SU, Lee JH, Jeon SH, Kim JW, Kang C, Yeo I, Kim J. An Herbal Medicine, Yukgunja-Tang is more Effective in a Type of Functional Dyspepsia Categorized by Facial Shape Diagnosis: A Placebo-Controlled, Double-Blind, Randomized Trial. Evid Based Complement Alternat Med 2018;2018:8546357. [PMID: 30363994 DOI: 10.1155/2018/8546357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Fukudo S, Endo Y, Hongo M, Nakajima A, Abe T, Kobayashi H, Nakata T, Nakajima T, Sameshima K, Kaku K, Shoji E, Tarumi K, Nagaoka Y, Ooshima T, Ozawa K, Majima T, Kamata S, Tada T, Ishii H, Segawa Y, Miyazaki S, Yamamoto T, Yagi Y, Sawada H, Shirota S, Otsuka S, Yamada N, Suzuki R, Kurakata H, Nakai K, Syuji Y, Usui T, Yamamura M, Oishi T, Tanaka H. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Gastroenterology & Hepatology 2018;3:603-13. [DOI: 10.1016/s2468-1253(18)30165-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
38 Barajas-nava LA, Consuelo Sánchez A, Castilla-peon M, Pizarro-castellanos MP, Vazquez Frias R. Probiotics for the treatment of irritable bowel syndrome in children. Cochrane Database of Systematic Reviews 2018. [DOI: 10.1002/14651858.cd013095] [Reference Citation Analysis]
39 van Zanten SV. In IBS with constipation, plecanatide reduced abdominal pain and increased bowel movements at 12 wk. Ann Intern Med 2018;169:JC11. [DOI: 10.7326/acpjc-2018-169-2-011] [Reference Citation Analysis]
40 Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, Gudleski GD, Hamilton FA, Katz LA, Krasner SS, Ma CX, Radziwon CD, Sitrin MD. Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. Gastroenterology 2018;155:47-57. [PMID: 29702118 DOI: 10.1053/j.gastro.2018.03.063] [Cited by in Crossref: 90] [Cited by in F6Publishing: 91] [Article Influence: 18.0] [Reference Citation Analysis]
41 Chung VCH, Wong CHL, Ching JYL, Sun WZ, Ju YL, Hung SS, Lin WL, Leung KC, Wong SYS, Wu JCY. Electroacupuncture plus standard of care for managing refractory functional dyspepsia: protocol of a pragmatic trial with economic evaluation. BMJ Open 2018;8:e018430. [PMID: 29593017 DOI: 10.1136/bmjopen-2017-018430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Elhusseiny MH, Amine AK, Salem OE, Tayel DI, Elsayed EA. Low FODMAP diet in Egyptian patients with Crohn's disease in remission phase with functional gastrointestinal symptoms. JGH Open. 2018;2:15-20. [PMID: 30483557 DOI: 10.1002/jgh3.12037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
43 Valeur J, Småstuen MC, Knudsen T, Lied GA, Røseth AG. Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome. Dig Dis Sci 2018;63:429-36. [PMID: 29302878 DOI: 10.1007/s10620-017-4893-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
44 Biasini B, Marchi L, Angelino D, Bedogni G, Zavaroni I, Pruneti C, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Passeri G, Ventura M, Del Rio D, Martini D. Claimed effects, outcome variables and methods of measurement for health claims on foods related to the gastrointestinal tract proposed under regulation (EC) 1924/2006. International Journal of Food Sciences and Nutrition 2018;69:771-804. [DOI: 10.1080/09637486.2018.1427220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet 2018;31:239-55. [DOI: 10.1111/jhn.12530] [Cited by in Crossref: 146] [Cited by in F6Publishing: 152] [Article Influence: 29.2] [Reference Citation Analysis]
46 Schiano di Visconte M, Santoro GA, Cracco N, Sarzo G, Bellio G, Brunner M, Cui Z, Matzel KE. Effectiveness of sacral nerve stimulation in fecal incontinence after multimodal oncologic treatment for pelvic malignancies: a multicenter study with 2-year follow-up. Tech Coloproctol 2018;22:97-105. [DOI: 10.1007/s10151-017-1745-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
47 Tungland B. Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. Human Microbiota in Health and Disease 2018. [DOI: 10.1016/b978-0-12-814649-1.00006-5] [Reference Citation Analysis]
48 O'Keeffe M, Jansen C, Martin L, Williams M, Seamark L, Staudacher HM, Irving PM, Whelan K, Lomer MC. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil 2018;30. [PMID: 28707437 DOI: 10.1111/nmo.13154] [Cited by in Crossref: 108] [Cited by in F6Publishing: 106] [Article Influence: 21.6] [Reference Citation Analysis]
49 Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. J Crohns Colitis 2017;11:1420-9. [PMID: 28525543 DOI: 10.1093/ecco-jcc/jjx073] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 12.7] [Reference Citation Analysis]
50 Rich G, Shah A, Koloski N, Funk P, Stracke B, Köhler S, Holtmann G. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol Motil 2017;29. [PMID: 28695660 DOI: 10.1111/nmo.13132] [Cited by in Crossref: 37] [Cited by in F6Publishing: 88] [Article Influence: 6.2] [Reference Citation Analysis]
51 Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology 2017;153:936-47. [PMID: 28625832 DOI: 10.1053/j.gastro.2017.06.010] [Cited by in Crossref: 255] [Cited by in F6Publishing: 257] [Article Influence: 42.5] [Reference Citation Analysis]
52 Gudleski GD, Satchidanand N, Dunlap LJ, Tahiliani V, Li X, Keefer L, Lackner JM; IBSOS Outcome Study Research Group. Predictors of medical and mental health care use in patients with irritable bowel syndrome in the United States. Behav Res Ther 2017;88:65-75. [PMID: 28110677 DOI: 10.1016/j.brat.2016.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
53 Pinheiro I, Robinson L, Verhelst A, Marzorati M, Winkens B, den Abbeele PV, Possemiers S. A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial. BMC Complement Altern Med 2017;17:441. [PMID: 28870194 DOI: 10.1186/s12906-017-1948-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
54 Arevalo‐villena M, Briones‐perez A, Corbo M, Sinigaglia M, Bevilacqua A. Biotechnological application of yeasts in food science: Starter cultures, probiotics and enzyme production. J Appl Microbiol 2017;123:1360-72. [DOI: 10.1111/jam.13548] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
55 Harvie RM, Chisholm AW, Bisanz JE, Burton JP, Herbison P, Schultz K, Schultz M. Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World J Gastroenterol 2017; 23(25): 4632-4643 [PMID: 28740352 DOI: 10.3748/wjg.v23.i25.4632] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 77] [Article Influence: 13.3] [Reference Citation Analysis]
56 Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, Halpern Z, Maharshak N, Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil 2017;29. [PMID: 28271623 DOI: 10.1111/nmo.13037] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
57 Flik CE, Bakker L, Laan W, van Rood YR, Smout AJPM, de Wit NJ. Systematic review: The placebo effect of psychological interventions in the treatment of irritable bowel syndrome. World J Gastroenterol 2017; 23(12): 2223-2233 [PMID: 28405151 DOI: 10.3748/wjg.v23.i12.2223] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
58 Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol 2017; 23(2): 336-344 [PMID: 28127207 DOI: 10.3748/wjg.v23.i2.336] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
59 Hod K, Ringel Y. Treatment of Functional Bowel Disorders With Prebiotics and Probiotics. The Microbiota in Gastrointestinal Pathophysiology 2017. [DOI: 10.1016/b978-0-12-804024-9.00038-0] [Reference Citation Analysis]
60 Carbone F, Vandenberghe A, Holvoet L, Vanuytsel T, Van Oudenhove L, Jones M, Tack J. Validation of the Leuven Postprandial Distress Scale, a questionnaire for symptom assessment in the functional dyspepsia/postprandial distress syndrome. Aliment Pharmacol Ther 2016;44:989-1001. [PMID: 27518319 DOI: 10.1111/apt.13753] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
61 Eales J, Gibson P, Whorwell P, Kellow J, Yellowlees A, Perry RH, Edwards M, King S, Wood H, Glanville J. Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population. Therap Adv Gastroenterol 2017;10:74-88. [PMID: 28286561 DOI: 10.1177/1756283X16670075] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
62 Christodoulides S, Dimidi E, Fragkos KC, Farmer AD, Whelan K, Scott SM. Systematic review with meta-analysis: effect of fibre supplementation on chronic idiopathic constipation in adults. Aliment Pharmacol Ther 2016;44:103-16. [PMID: 27170558 DOI: 10.1111/apt.13662] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 9.6] [Reference Citation Analysis]
63 Weizman Z, Abu-abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Pediatrics 2016;174:160-164.e1. [DOI: 10.1016/j.jpeds.2016.04.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
64 Mckenzie YA, Thompson J, Gulia P, Lomer MCE; (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association). British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 2016;29:576-92. [DOI: 10.1111/jhn.12386] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
65 Han G, Leem J, Lee H, Lee J. Electroacupuncture to treat gastroesophageal reflux disease: study protocol for a randomized controlled trial. Trials 2016;17:246. [PMID: 27188910 DOI: 10.1186/s13063-016-1371-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
66 Prince AC, Myers CE, Joyce T, Irving P, Lomer M, Whelan K. Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1129-36. [PMID: 26914438 DOI: 10.1097/MIB.0000000000000708] [Cited by in Crossref: 119] [Cited by in F6Publishing: 101] [Article Influence: 17.0] [Reference Citation Analysis]
67 Lauche R, Kumar S, Hallmann J, Lüdtke R, Rampp T, Dobos G, Langhorst J. Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial. Complement Ther Med 2016;26:171-7. [PMID: 27261998 DOI: 10.1016/j.ctim.2016.04.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
68 Knowles SR, Austin DW, Sivanesan S, Tye-Din J, Leung C, Wilson J, Castle D, Kamm MA, Macrae F, Hebbard G. Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. Psychol Health Med. 2017;22:524-534. [PMID: 27045996 DOI: 10.1080/13548506.2016.1168932] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
69 Nassar-Sheikh Rashid A, Taminiau JA, Benninga MA, Saps M, Tabbers MM. Definitions and Outcome Measures in Pediatric Functional Upper Gastrointestinal Tract Disorders: A Systematic Review. J Pediatr Gastroenterol Nutr 2016;62:581-7. [PMID: 26348686 DOI: 10.1097/MPG.0000000000000973] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
70 Simrén M, Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H. Reply. Gastroenterology 2016;150:1047-8. [PMID: 26930012 DOI: 10.1053/j.gastro.2016.02.068] [Reference Citation Analysis]
71 Thijssen AY, Clemens CH, Vankerckhoven V, Goossens H, Jonkers DM, Masclee AA. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2016;28:8-14. [PMID: 26469356 DOI: 10.1097/MEG.0000000000000484] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
72 Barbara G, Cremon C, Annese V, Basilisco G, Bazzoli F, Bellini M, Benedetti A, Benini L, Bossa F, Buldrini P, Cicala M, Cuomo R, Germanà B, Molteni P, Neri M, Rodi M, Saggioro A, Scribano ML, Vecchi M, Zoli G, Corinaldesi R, Stanghellini V. Randomised controlled trial of mesalazine in IBS. Gut 2016;65:82-90. [PMID: 25533646 DOI: 10.1136/gutjnl-2014-308188] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]
73 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms. EFS2 2016;14. [DOI: 10.2903/j.efsa.2016.4369] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
74 European Food Safety Authority (EFSA). Outcome of a public consultation on the draft guidance of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms. EFSA Supporting Publications 2016;13. [DOI: 10.2903/sp.efsa.2016.en-985] [Reference Citation Analysis]
75 Eftekhari K, Vahedi Z, Kamali Aghdam M, Noemi Diaz D. A Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus reuteri for Chronic Functional Abdominal Pain in Children. Iran J Pediatr 2015;25:e2616. [PMID: 26635937 DOI: 10.5812/ijp.2616] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
76 Smith EM, Foster HE, Beresford MW. The development and assessment of biological treatments for children. Br J Clin Pharmacol 2015;79:379-94. [PMID: 24750505 DOI: 10.1111/bcp.12406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
77 Friesen CA, Schurman JV, Abdel-Rahman SM. Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest. World J Gastrointest Pharmacol Ther 2015; 6(4): 96-104 [PMID: 26558142 DOI: 10.4292/wjgpt.v6.i4.96] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
78 Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Simrén M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 2015;149:1399-1407.e2. [PMID: 26255043 DOI: 10.1053/j.gastro.2015.07.054] [Cited by in Crossref: 376] [Cited by in F6Publishing: 383] [Article Influence: 47.0] [Reference Citation Analysis]
79 Palsson OS. Hypnosis Treatment of Gastrointestinal Disorders: A Comprehensive Review of the Empirical Evidence. Am J Clin Hypn 2015;58:134-58. [PMID: 26264539 DOI: 10.1080/00029157.2015.1039114] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
80 Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, Afifi AF, El-Khayat HR, Nouh A, Hassan MF, Fatah AA, Rucker Joerg I, Sánchez Núñez JM, Osthoff Rueda R, Jurkowska G, Walczak M, Malecka-Panas E, Linke K, Hartleb M, Janssen-van Solingen G. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig 2014;34:783-93. [PMID: 25258162 DOI: 10.1007/s40261-014-0233-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
81 Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, Morberg CM. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 2015;114:1638-1646. [PMID: 26382580 DOI: 10.1017/s0007114515003347] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
82 Krarup AL, Peterson E, Ringström G, Törnblom H, Hjortswang H, Simrén M. The Short Health Scale: A Simple, Valid, Reliable, and Responsive Way of Measuring Subjective Health in Patients With Irritable Bowel Syndrome. J Clin Gastroenterol 2015;49:565-70. [PMID: 25216385 DOI: 10.1097/MCG.0000000000000209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
83 Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 2015;42:418-27. [PMID: 26104013 DOI: 10.1111/apt.13286] [Cited by in Crossref: 241] [Cited by in F6Publishing: 262] [Article Influence: 30.1] [Reference Citation Analysis]
84 Self MM, Williams AE, Czyzewski DI, Weidler EM, Shulman RJ. Agreement between prospective diary data and retrospective questionnaire report of abdominal pain and stooling symptoms in children with irritable bowel syndrome. Neurogastroenterol Motil 2015;27:1110-9. [PMID: 26017930 DOI: 10.1111/nmo.12590] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
85 Lövdahl J, Ringström G, Agerforz P, Törnblom H, Simrén M. Nurse-Administered, Gut-Directed Hypnotherapy in IBS: Efficacy and Factors Predicting a Positive Response. Am J Clin Hypn 2015;58:100-14. [PMID: 26046719 DOI: 10.1080/00029157.2015.1030492] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
86 Choi MG, Rhee PL, Park H, Lee OY, Lee KJ, Choi SC, Seol SY, Chun HJ, Rew JS, Lee DH. Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia. J Neurogastroenterol Motil. 2015;21:414-422. [PMID: 26130637 DOI: 10.5056/jnm14117] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
87 Lu B, Li M, Hu Y, Xu Y, Zhang S, Cai LJ. Effect of peroral esophageal myotomy for achalasia treatment: A Chinese study. World J Gastroenterol 2015; 21(18): 5622-5629 [PMID: 25987787 DOI: 10.3748/wjg.v21.i18.5622] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
88 Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil 2015;27:705-16. [PMID: 25809913 DOI: 10.1111/nmo.12544] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
89 Whigham L, Joyce T, Harper G, Irving PM, Staudacher HM, Whelan K, Lomer MCE. Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. J Hum Nutr Diet 2015;28:687-96. [DOI: 10.1111/jhn.12318] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
90 Camilleri M, Lembo AJ, Lavins BJ, MacDougall JE, Carson RT, Williams VS, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United European Gastroenterol J 2015;3:53-62. [PMID: 25653859 DOI: 10.1177/2050640614555946] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
91 Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015;47:119-24. [PMID: 25488056 DOI: 10.1016/j.dld.2014.11.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 8.6] [Reference Citation Analysis]
92 European Food Safety Authority (EFSA). Outcome of a public consultation on the discussion paper for the revision of the guidance on the scientific requirements for health claims related to gut and immune function. EFSA Supporting Publications 2015;12. [DOI: 10.2903/sp.efsa.2015.en-758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Sanchez JE, Brenner DM, Franklin H, Yu J, Barrett AC, Paterson C. Validity of the ≥50% Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence. Clin Transl Gastroenterol 2015;6:e70. [PMID: 25588523 DOI: 10.1038/ctg.2014.20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
94 Miwa H, Kusano M, Arisawa T, Oshima T, Kato M, Joh T, Suzuki H, Tominaga K, Nakada K, Nagahara A. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol. 2015;50:125-139. [PMID: 25586651 DOI: 10.1007/s00535-014-1016-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
95 Miwa H, Kusano M, Arisawa T, Oshima T, Kato M, Joh T, Suzuki H, Tominaga K, Nakada K, Nagahara A, Futagami S, Manabe N, Inui A, Haruma K, Higuchi K, Yakabi K, Hongo M, Uemura N, Kinoshita Y, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol 2015;50:125-39. [DOI: 10.1007/s00535-014-1022-3] [Cited by in Crossref: 122] [Cited by in F6Publishing: 98] [Article Influence: 15.3] [Reference Citation Analysis]
96 European Food Safety Authority (EFSA). Response to comments on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to Bimuno® GOS and reducing gastro‐intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Supporting Publications 2015;12. [DOI: 10.2903/sp.efsa.2015.en-728] [Reference Citation Analysis]
97 Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015;64:84-92. [PMID: 24727487 DOI: 10.1136/gutjnl-2013-305965] [Cited by in Crossref: 137] [Cited by in F6Publishing: 101] [Article Influence: 17.1] [Reference Citation Analysis]
98 Alrubaiy L, Hutchings HA, Williams JG. Assessing patient reported outcome measures: A practical guide for gastroenterologists. United European Gastroenterol J. 2014;2:463-470. [PMID: 25452841 DOI: 10.1177/2050640614558345] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
99 Lackner JM, Jaccard J, Keefer L, Firth R, Carosella AM, Sitrin M, Brenner D; Representing the IBSOS Research Group. The accuracy of patient-reported measures for GI symptoms: a comparison of real time and retrospective reports. Neurogastroenterol Motil 2014;26:1802-11. [PMID: 25424582 DOI: 10.1111/nmo.12466] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
100 Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A. Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil 2014;26:1642-50. [PMID: 25244442 DOI: 10.1111/nmo.12444] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
101 Stanghellini V, Cogliandro R. Review article: adherence to Rome criteria in therapeutic trials in functional dyspepsia. Aliment Pharmacol Ther 2014;40:435-66. [PMID: 25056101 DOI: 10.1111/apt.12865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
102 Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1350-65; quiz 1366. [PMID: 24935275 DOI: 10.1038/ajg.2014.148] [Cited by in Crossref: 281] [Cited by in F6Publishing: 286] [Article Influence: 31.2] [Reference Citation Analysis]
103 Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100:1075-1084. [PMID: 25099542 DOI: 10.3945/ajcn.114.089151] [Cited by in Crossref: 172] [Cited by in F6Publishing: 182] [Article Influence: 19.1] [Reference Citation Analysis]
104 Schurman JV, Kessler ED, Friesen CA. Understanding and Treatment of Chronic Abdominal Pain in Pediatric Primary Care. Clin Pediatr (Phila) 2014;53:1032-40. [DOI: 10.1177/0009922814545162] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
105 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to Bimuno ® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006: Bimuno® GOS and reducing gastro-intestinal discomfort. EFSA Journal 2014;12:3756. [DOI: 10.2903/j.efsa.2014.3756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
106 Pourmoghaddas Z, Saneian H, Roohafza H, Gholamrezaei A. Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Biomed Res Int. 2014;2014:191026. [PMID: 25089264 DOI: 10.1155/2014/191026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
107 Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, Tayebi A, Hashemi H, Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res. 2014;3:140. [PMID: 25161987 DOI: 10.4103/2277-9175.135157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
108 Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2014;12:953-9.e4. [PMID: 24315882 DOI: 10.1016/j.cgh.2013.11.024] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
109 Buchwald-Werner S, Fujii H, Reule C, Schoen C. Perilla extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study. BMC Complement Altern Med 2014;14:173. [PMID: 24885816 DOI: 10.1186/1472-6882-14-173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
110 Lim CH, Choi MG, Baeg MK, Moon SJ, Kim JS, Cho YK, Park JM, Lee IS, Kim SW, Choi KY. Applying novel nutrient drink to clinical trial of functional dyspepsia. J Neurogastroenterol Motil 2014;20:219-27. [PMID: 24840374 DOI: 10.5056/jnm.2014.20.2.219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and improvement of bowel function by increasing stool frequency pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFS2 2014;12. [DOI: 10.2903/j.efsa.2014.3659] [Reference Citation Analysis]
112 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFS2 2014;12. [DOI: 10.2903/j.efsa.2013.3658] [Reference Citation Analysis]
113 Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 2014;11:256-66. [PMID: 24445613 DOI: 10.1038/nrgastro.2013.259] [Cited by in Crossref: 165] [Cited by in F6Publishing: 145] [Article Influence: 18.3] [Reference Citation Analysis]
114 Han G, Ko SJ, Park JW, Kim J, Yeo I, Lee H, Kim SY, Lee H. Acupuncture for functional dyspepsia: study protocol for a two-center, randomized controlled trial. Trials. 2014;15:89. [PMID: 24655542 DOI: 10.1186/1745-6215-15-89] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
115 Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition. 2014;30:1151-1157. [PMID: 25194614 DOI: 10.1016/j.nut.2014.02.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
116 Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, Treem W. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. J Pediatr Gastroenterol Nutr 2014;58:226-36. [PMID: 24121146 DOI: 10.1097/MPG.0000000000000195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
117 Chumpitazi BP, Hollister EB, Oezguen N, Tsai CM, McMeans AR, Luna RA, Savidge TC, Versalovic J, Shulman RJ. Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome. Gut Microbes. 2014;5:165-175. [PMID: 24637601 DOI: 10.4161/gmic.27923] [Cited by in Crossref: 95] [Cited by in F6Publishing: 104] [Article Influence: 10.6] [Reference Citation Analysis]
118 Mohammad S, Di Lorenzo C, Youssef NN, Miranda A, Nurko S, Hyman P, Saps M. Assessment of abdominal pain through global outcomes and recent FDA recommendations in children: are we ready for change? J Pediatr Gastroenterol Nutr 2014;58:46-50. [PMID: 23857339 DOI: 10.1097/MPG.0b013e3182a20764] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
119 Parkman HP, Van Natta ML, Abell TL, McCallum RW, Sarosiek I, Nguyen L, Snape WJ, Koch KL, Hasler WL, Farrugia G, Lee L, Unalp-Arida A, Tonascia J, Hamilton F, Pasricha PJ. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2013;310:2640-9. [PMID: 24368464 DOI: 10.1001/jama.2013.282833] [Cited by in Crossref: 118] [Cited by in F6Publishing: 123] [Article Influence: 11.8] [Reference Citation Analysis]
120 Krokowicz L, Stojcev Z, Kaczmarek BF, Kociemba W, Kaczmarek E, Walkowiak J, Krokowicz P, Drews M, Banasiewicz T. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study. Int J Colorectal Dis 2014;29:387-93. [PMID: 24343275 DOI: 10.1007/s00384-013-1807-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
121 Meltzer AC, Bregman B, Blanchard J. Depression is associated with repeat emergency department visits in patients with non-specific abdominal pain. West J Emerg Med 2014;15:325-8. [PMID: 24868312 DOI: 10.5811/westjem.2013.7.15635] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
122 Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro-Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014;68:245-254. [PMID: 24147869 DOI: 10.1111/ijcp.12333] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
123 Park JW, Lee BH, Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complement Altern Med 2013;13:247. [PMID: 24088418 DOI: 10.1186/1472-6882-13-247] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
124 Di Nardo G, Oliva S, Ferrari F, Mallardo S, Barbara G, Cremon C, Aloi M, Cucchiara S. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. BMC Gastroenterol 2013;13:142. [PMID: 24063420 DOI: 10.1186/1471-230X-13-142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
125 Lacy BE, Wang F, Bhowal S, Schaefer E; study group. On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. Scand J Gastroenterol 2013;48:926-35. [PMID: 23865591 DOI: 10.3109/00365521.2013.804117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
126 Horvath A, Dziechciarz P, Szajewska H. Systematic review of randomized controlled trials: fiber supplements for abdominal pain-related functional gastrointestinal disorders in childhood. Ann Nutr Metab 2012;61:95-101. [PMID: 22889919 DOI: 10.1159/000338965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
127 Horvath A, Dziechciarz P, Szajewska H. Glucomannan for abdominal pain-related functional gastrointestinal disorders in children: A randomized trial. World J Gastroenterol 2013; 19(20): 3062-3068 [PMID: 23716985 DOI: 10.3748/wjg.v19.i20.3062] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
128 Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am J Gastroenterol 2013;108:718-27. [PMID: 23545709 DOI: 10.1038/ajg.2013.63] [Cited by in Crossref: 277] [Cited by in F6Publishing: 277] [Article Influence: 27.7] [Reference Citation Analysis]
129 Gulewitsch MD, Müller J, Hautzinger M, Schlarb AA. Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and irritable bowel syndrome in childhood: a randomized controlled trial. Eur J Pediatr. 2013;172:1043-1051. [PMID: 23568514 DOI: 10.1007/s00431-013-1990-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
130 Marteau P, Guyonnet D, Lafaye de Micheaux P, Gelu S. A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms. Neurogastroenterol Motil 2013;25:331-e252. [PMID: 23480238 DOI: 10.1111/nmo.12078] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
131 Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol. 2013;13:45. [PMID: 23496803 DOI: 10.1186/1471-230x-13-45] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]
132 Guyonnet D, Naliboff B, Rondeau P, Mayer E, Chassany O. Gastrointestinal well-being in subjects reporting mild gastrointestinal discomfort: characteristics and properties of a global assessment measure. Br J Nutr 2013;110:1263-71. [PMID: 23432848 DOI: 10.1017/S0007114513000275] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
133 Perez-lloret S, Rey MV, Pavy-le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opinion on Emerging Drugs 2013;18:39-53. [DOI: 10.1517/14728214.2013.766168] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
134 Banasiewicz T, Krokowicz Ł, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013;15:204-9. [PMID: 22738315 DOI: 10.1111/j.1463-1318.2012.03152.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
135 Lackner JM, Jaccard J, Baum C. Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores. Value Health 2013;16:97-103. [PMID: 23337220 DOI: 10.1016/j.jval.2012.08.2207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
136 Boeckxstaens G, Corazziari ES, Mearin F, Tack J. IBS and the role of otilonium bromide. Int J Colorectal Dis. 2013;28:295-304. [PMID: 23178991 DOI: 10.1007/s00384-012-1598-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
137 Krol R, Smeenk RJ, van Lin EN, Hopman WP. Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy. Int J Colorectal Dis 2013;28:519-26. [PMID: 23080344 DOI: 10.1007/s00384-012-1593-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
138 Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18(30): 4012-4018 [PMID: 22912552 DOI: 10.3748/wjg.v18.i30.4012] [Cited by in CrossRef: 166] [Cited by in F6Publishing: 171] [Article Influence: 15.1] [Reference Citation Analysis]
139 European Food Safety Authority (EFSA). Response to comments on the Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro‐intestinal discomfort pursuant to Article 13.5 of Regulation (EC) No 1924/2006. EFSA Supporting Publications 2012;9. [DOI: 10.2903/sp.efsa.2012.en-329] [Reference Citation Analysis]
140 Ringström G, Störsrud S, Simrén M. A comparison of a short nurse-based and a long multidisciplinary version of structured patient education in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2012;24:950-7. [PMID: 22617366 DOI: 10.1097/MEG.0b013e328354f41f] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
141 Lackner JM, Keefer L, Jaccard J, Firth R, Brenner D, Bratten J, Dunlap LJ, Ma C, Byroads M; IBSOS Research Group. The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome. Contemp Clin Trials 2012;33:1293-310. [PMID: 22846389 DOI: 10.1016/j.cct.2012.07.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
142 Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142:1510-1518. [PMID: 22739368 DOI: 10.3945/jn.112.159285] [Cited by in Crossref: 359] [Cited by in F6Publishing: 380] [Article Influence: 32.6] [Reference Citation Analysis]
143 Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, Berman BM, Lao L. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2012;107:835-47; quiz 848. [PMID: 22488079 DOI: 10.1038/ajg.2012.66] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 6.9] [Reference Citation Analysis]
144 Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5:CD005111. [PMID: 22592702 DOI: 10.1002/14651858.cd005111.pub3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 47] [Article Influence: 2.5] [Reference Citation Analysis]
145 Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5:CD005111. [PMID: 22592702 DOI: 10.1002/14651858.cd005111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
146 Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5:CD005111. [PMID: 22592702 DOI: 10.10002/14651858.CD005111.pub3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J Gastroenterol 2012; 18(17): 2067-2075 [PMID: 22563194 DOI: 10.3748/wjg.v18.i17.2067] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
148 Huang CH, Lin JS, Li TC, Lee SC, Wang HP, Lue HC, Su YC. Comparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long-Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled Trial. Evid Based Complement Alternat Med 2012;2012:923190. [PMID: 22474530 DOI: 10.1155/2012/923190] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
149 Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-7. [PMID: 22157240 DOI: 10.1097/MCG.0b013e31823712b1] [Cited by in Crossref: 142] [Cited by in F6Publishing: 143] [Article Influence: 12.9] [Reference Citation Analysis]
150 Shulman RJ, Smith EO. Does VSL#3 really improve symptoms in children with IBS? J Pediatr Gastroenterol Nutr 2012;54:109; author reply 109. [PMID: 22064630 DOI: 10.1097/MPG.0b013e31823df69b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Flik CE, van Rood YR, Laan W, Smout AJ, Weusten BL, Whorwell PJ, de Wit NJ. A randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study). BMC Gastroenterol. 2011;11:137. [PMID: 22185606 DOI: 10.1186/1471-230X-11-137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
152 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006: Bimuno® GOS and reducing gastro-intestinal discomfort. EFSA Journal 2011;9:2472. [DOI: 10.2903/j.efsa.2011.2472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
153 Gallagher AM, Meijer GW, Richardson DP, Rondeau V, Skarp M, Stasse-wolthuis M, Tweedie GC, Witkamp R. A standardised approach towards PROving the efficacy of foods and food constituents for health CLAIMs (PROCLAIM): providing guidance. Br J Nutr 2011;106:S16-28. [DOI: 10.1017/s0007114511003618] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
154 He WR, Zhang FC, Liang LX. Mixed 5-HT3 antagonists/5-HT4 agonists for irritable bowel syndrome: a systematic review. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3277-3283 [DOI: 10.11569/wcjd.v19.i31.3277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Lackner J, Jaccard J, Baum C, Smith A, Krasner S, Katz L, Firth R, Raby T, Powell C. Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors. Clin Gastroenterol Hepatol 2011;9:957-964.e1. [PMID: 21699821 DOI: 10.1016/j.cgh.2011.06.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
156 Desborough MJ, Ford AC. Is otilonium bromide globally effective in irritable bowel syndrome? Aliment Pharmacol Ther 2011;34:1034-5; author reply 1035-6. [PMID: 21933208 DOI: 10.1111/j.1365-2036.2011.04769.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
157 Norquist JM, Girman C, Fehnel S, DeMuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res 2012;21:1013-20. [PMID: 21909804 DOI: 10.1007/s11136-011-0003-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
158 Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011;:CD003460. [PMID: 21833945 DOI: 10.1002/14651858.CD003460.pub3] [Cited by in Crossref: 107] [Cited by in F6Publishing: 166] [Article Influence: 8.9] [Reference Citation Analysis]
159 Chmielewska A, Horvath A, Dziechciarz P, Szajewska H. Glucomannan is not effective for the treatment of functional constipation in children: A double-blind, placebo-controlled, randomized trial. Clinical Nutrition 2011;30:462-8. [DOI: 10.1016/j.clnu.2011.01.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
160 Bartlett L, Sloots K, Nowak M, Ho Y. Biofeedback therapy for symptoms of bowel dysfunction following surgery for colorectal cancer. Tech Coloproctol 2011;15:319-26. [DOI: 10.1007/s10151-011-0713-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
161 Sainsbury A, Ford AC. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therap Adv Gastroenterol. 2011;4:115-127. [PMID: 21694813 DOI: 10.1177/1756283x10387203] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
162 Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011;23:544-e205. [PMID: 21303430 DOI: 10.1111/j.1365-2982.2011.01668.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
163 Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011;33:1302-10. [PMID: 21507030 DOI: 10.1111/j.1365-2036.2011.04665.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 11.3] [Reference Citation Analysis]
164 Coffin B, Bortolloti C, Bourgeois O, Denicourt L. Efficacy of a simethicone, activated charcoal and magnesium oxide combination (Carbosymag®) in functional dyspepsia: results of a general practice-based randomized trial. Clin Res Hepatol Gastroenterol. 2011;35:494-499. [PMID: 21478070 DOI: 10.1016/j.clinre.2011.02.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
165 Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 2011;33:895-901. [PMID: 21332763 DOI: 10.1111/j.1365-2036.2011.04602.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 162] [Article Influence: 15.0] [Reference Citation Analysis]
166 Ang D, Talley NJ, Simren M, Janssen P, Boeckxstaens G, Tack J. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-49. [PMID: 21223343 DOI: 10.1111/j.1365-2036.2010.04566.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
167 Czyzewski DI, Lane MM, Weidler EM, Williams AE, Swank PR, Shulman RJ. The interpretation of Rome III criteria and method of assessment affect the irritable bowel syndrome classification of children. Aliment Pharmacol Ther 2011;33:403-11. [PMID: 21138454 DOI: 10.1111/j.1365-2036.2010.04535.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
168 Coffin B. Syndrome de l’intestin irritable: traitements conventionnels et alternatifs. Post’U FMC-HGE 2011. [DOI: 10.1007/978-2-8178-0237-4_10] [Reference Citation Analysis]
169 Ljótsson B, Hedman E, Lindfors P, Hursti T, Lindefors N, Andersson G, Rück C. Long-term follow-up of internet-delivered exposure and mindfulness based treatment for irritable bowel syndrome. Behav Res Ther. 2011;49:58-61. [PMID: 21092934 DOI: 10.1016/j.brat.2010.10.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 5.2] [Reference Citation Analysis]
170 Shinozaki M, Kanazawa M, Kano M, Endo Y, Nakaya N, Hongo M, Fukudo S. Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. Appl Psychophysiol Biofeedback. 2010;35:189-198. [PMID: 19997775 DOI: 10.1007/s10484-009-9125-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
171 Hsu YC, Liou JM, Yang TH, Hsu WL, Lin HJ, Wu HT, Lin JT, Wang HP, Wu MS. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol. 2011;46:183-190. [PMID: 20957498 DOI: 10.1007/s00535-010-0334-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
172 Wong RK, Drossman DA. Quality of life measures in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2010;4:277-284. [PMID: 20528115 DOI: 10.1586/egh.10.19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
173 van Zanten SV. Functional Dyspepsia. Evidence‐Based Gastroenterology and Hepatology 2010. [DOI: 10.1002/9781444314403.ch9] [Reference Citation Analysis]
174 Ljótsson B, Andréewitch S, Hedman E, Rück C, Andersson G, Lindefors N. Exposure and mindfulness based therapy for irritable bowel syndrome – An open pilot study. Journal of Behavior Therapy and Experimental Psychiatry 2010;41:185-90. [DOI: 10.1016/j.jbtep.2010.01.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
175 Dorn SD. Systematic review: self-management support interventions for irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:513-21. [PMID: 20497137 DOI: 10.1111/j.1365-2036.2010.04374.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
176 Ford AC. Renzapride in IBS: is efficacy in the eye of the beholder? Aliment Pharmacol Ther 2010;32:113-4; author reply 114-5. [PMID: 20597877 DOI: 10.1111/j.1365-2036.2010.04275.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
177 Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58. [PMID: 20412064 DOI: 10.1111/j.1365-2036.2010.04328.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 134] [Article Influence: 11.6] [Reference Citation Analysis]
178 Jung HK. Comments on tegaserod trial on irritable bowel syndrome. J Neurogastroenterol Motil 2010;16:222. [PMID: 20535361 DOI: 10.5056/jnm.2010.16.2.222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Lackner JM, Gudleski GD, Keefer L, Krasner SS, Powell C, Katz LA. Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010;8:426-32. [PMID: 20170751 DOI: 10.1016/j.cgh.2010.02.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
180 Chang L, Drossman DA. Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. Am J Gastroenterol 2010;105:722-30. [PMID: 20372120 DOI: 10.1038/ajg.2010.49] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
181 Ford AC. Probiotics in irritable bowel syndrome: underachievers or underpowered? Aliment Pharmacol Ther 2010;31:922-3; author reply 923-4. [PMID: 20415830 DOI: 10.1111/j.1365-2036.2009.04223.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
182 Slockers M. Let op zorgwekkende zorgmijders. HUISARTS WETENSCHAP 2010;53:239-239. [DOI: 10.1007/s12445-010-0100-x] [Reference Citation Analysis]
183 Bijkerk CJ, de Wit NJ, Hoes AW, Muris JWM, Knottnerus JA, Whorwell PJ. Oplosbare of niet-oplosbare vezels: wat werkt beter bij het prikkelbaredarmsyndroom? HUISARTS WETENSCHAP 2010;53:195-202. [DOI: 10.1007/s12445-010-0087-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Kim YS, Choi SC. Reply. J Neurogastroenterol Motil 2010;16:222-3. [PMID: 20535360 DOI: 10.5056/jnm.2010.16.2.223] [Reference Citation Analysis]
185 Ford AC. Alverine citrate, simeticone, and Rome III irritable bowel syndrome. Aliment Pharmacol Ther 2010;31:767-8; author reply 768-9. [PMID: 20415841 DOI: 10.1111/j.1365-2036.2009.04222.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
186 Ljótsson B, Falk L, Vesterlund AW, Hedman E, Lindfors P, Rück C, Hursti T, Andréewitch S, Jansson L, Lindefors N. Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome--a randomized controlled trial. Behav Res Ther. 2010;48:531-539. [PMID: 20362976 DOI: 10.1016/j.brat.2010.03.003] [Cited by in Crossref: 169] [Cited by in F6Publishing: 179] [Article Influence: 13.0] [Reference Citation Analysis]
187 Martens U, Enck P, Zieseniss E. Probiotic treatment of irritable bowel syndrome in children. Ger Med Sci. 2010;8:Doc07. [PMID: 20234804 DOI: 10.3205/000096] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
188 Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010;31:615-24. [PMID: 20003095 DOI: 10.1111/j.1365-2036.2009.04216.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
189 Helgeland H, Sandvik L, Mathiesen KS, Kristensen H. Childhood predictors of recurrent abdominal pain in adolescence: A 13-year population-based prospective study. J Psychosom Res 2010;68:359-67. [PMID: 20307703 DOI: 10.1016/j.jpsychores.2009.10.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
190 Bellini M, Bove A, Sormani MP, Battaglia E, Bocchini R, Alduini P, Bassotti G, Bruzzi P, Pucciani F; Italian Constipation Study Group. The daily diary and the questionnaire are not equivalent for the evaluation of bowel habits. Dig Liver Dis 2010;42:99-102. [PMID: 19473896 DOI: 10.1016/j.dld.2009.04.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
191 Haller D, Antoine JM, Bengmark S, Enck P, Rijkers GT, Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J Nutr. 2010;140:690S-697S. [PMID: 20107148 DOI: 10.3945/jn.109.113746] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
192 Duracinsky M, Chassany O. [How can an effective drug to treat irritable bowel syndrome be successfully developed?]. Gastroenterol Clin Biol 2009;33 Suppl 1:S26-34. [PMID: 19303535 DOI: 10.1016/S0399-8320(09)71522-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
193 Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain 2009;25:797-807. [PMID: 19851161 DOI: 10.1097/AJP.0b013e3181b12dec] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 4.5] [Reference Citation Analysis]
194 Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology 2009;137:1944-53.e1-3. [PMID: 19706292 DOI: 10.1053/j.gastro.2009.08.047] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
195 Gholamrezaei A, Nemati K, Emami MH. Which end point is more comprehensive in reflecting changes in irritable bowel syndrome treatment trials? Am J Gastroenterol 2009;104:2859. [PMID: 19888249 DOI: 10.1038/ajg.2009.486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
196 Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. Dis Colon Rectum 2009;52:1730-7. [PMID: 19966605 DOI: 10.1007/DCR.0b013e3181b55455] [Cited by in Crossref: 179] [Cited by in F6Publishing: 154] [Article Influence: 12.8] [Reference Citation Analysis]
197 Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. [PMID: 19713235 DOI: 10.1136/bmj.b3154.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
198 Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. [PMID: 19713235 DOI: 10.1136/bmj.b3154] [Cited by in Crossref: 147] [Cited by in F6Publishing: 218] [Article Influence: 10.5] [Reference Citation Analysis]
199 Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr. 2009;102:1654-1662. [PMID: 19622191 DOI: 10.1017/s0007114509990882] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
200 Lecuyer M, Cousin T, Monnot M, Coffin B. Efficacy of an activated charcoal–simethicone combination in dyspeptic syndrome: Results of a placebo-controlled prospective study in general practice. Gastroentérologie Clinique et Biologique 2009;33:478-84. [DOI: 10.1016/j.gcb.2008.09.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
201 Camilleri M. Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome? Am J Gastroenterol 2009;104:920-2. [PMID: 19293789 DOI: 10.1038/ajg.2009.20] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
202 Passos MC, Lembo AJ, Conboy LA, Kaptchuk TJ, Kelly JM, Quilty MT, Kerr CE, Jacobson EE, Hu R, Friedlander E, Drossman DA. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol 2009;104:912-9. [PMID: 19293784 DOI: 10.1038/ajg.2009.13] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
203 Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-49; quiz 1050. [PMID: 19277023 DOI: 10.1038/ajg.2009.25] [Cited by in Crossref: 236] [Cited by in F6Publishing: 252] [Article Influence: 16.9] [Reference Citation Analysis]
204 Ran ZH, Yuan YZ, Li ZS, Wang JY, Zong CH, Xie WF, Zheng P, Chen SL, Zhan XB, Chen SY, Xiao SD. The efficacy of Combizym in the treatment of Chinese patients with dyspepsia: a multicenter, randomized, placebo-controlled and cross-over study: Shanghai Combizym Clinical Cooperative Group. J Dig Dis 2009;10:41-8. [PMID: 19236546 DOI: 10.1111/j.1751-2980.2008.00361.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
205 Guyonnet D, Woodcock A, Stefani B, Trevisan C, Hall C. Fermented milk containing Bifidobacterium lactis DN-173 010 improved self-reported digestive comfort amongst a general population of adults. A randomized, open-label, controlled, pilot study. J Dig Dis 2009;10:61-70. [PMID: 19236549 DOI: 10.1111/j.1751-2980.2008.00366.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
206 Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009;CD006442. [PMID: 19160286 DOI: 10.1002/14651858.cd006442.pub2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 101] [Article Influence: 5.2] [Reference Citation Analysis]
207 van Zanten SV. Dyspepsia and reflux in primary care: rough DIAMOND of a trial. The Lancet 2009;373:187-188. [DOI: 10.1016/s0140-6736(09)60051-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
208 Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008;135:1877-91. [PMID: 18848833 DOI: 10.1053/j.gastro.2008.09.005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
209 European Food Safety Authority (EFSA). LGG® MAX and gastro-intestinal discomfort - Scientific substantiation of a health claim related to LGG® MAX and reduction of gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006 - Scientific Opinion of the Panel on Dietet. EFSA Journal 2008;6:853. [DOI: 10.2903/j.efsa.2008.853] [Reference Citation Analysis]
210 Oliver KL, Jill Davies G. Heartburn: influence of diet and lifestyle. Nutrition & Food Science 2008;38:548-54. [DOI: 10.1108/00346650810920141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
211 Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, Kim YH, Kim JJ, Rhee JC, Rhee PL. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714-8. [PMID: 18274900 DOI: 10.1007/s10620-007-0196-4] [Cited by in Crossref: 100] [Cited by in F6Publishing: 107] [Article Influence: 6.7] [Reference Citation Analysis]
212 Enck P, Zimmermann K, Menke G, Müller-Lissner S, Martens U, Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome--a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008;20:1103-9. [PMID: 18565142 DOI: 10.1111/j.1365-2982.2008.01156.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
213 Lackner J, Jaccard J, Krasner S, Katz L, Gudleski G, Holroyd K. Self-Administered Cognitive Behavior Therapy for Moderate to Severe Irritable Bowel Syndrome: Clinical Efficacy, Tolerability, Feasibility. Clinical Gastroenterology and Hepatology 2008;6:899-906. [DOI: 10.1016/j.cgh.2008.03.004] [Cited by in Crossref: 125] [Cited by in F6Publishing: 98] [Article Influence: 8.3] [Reference Citation Analysis]
214 Lehman TJ. Are withdrawal trials in paediatric rheumatic disease helpful? Lancet 2008;372:348-50. [PMID: 18632148 DOI: 10.1016/S0140-6736(08)60999-X] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
215 Dent J, Kahrilas PJ, Vakil N, Van Zanten SV, Bytzer P, Delaney B, Haruma K, Hatlebakk J, McColl E, Moayyedi P, Stanghellini V, Tack J, Vaezi M. Clinical trial design in adult reflux disease: a methodological workshop. Aliment Pharmacol Ther 2008;28:107-26. [PMID: 18384662 DOI: 10.1111/j.1365-2036.2008.03700.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
216 Sinn DH, Kim JH, Kim S, Son HJ, Kim JJ, Rhee JC, Rhee PL. Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. Aliment Pharmacol Ther 2008;27:1275-81. [PMID: 18315581 DOI: 10.1111/j.1365-2036.2008.03659.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
217 Chang L. The trials and tribulations of drug development for functional gastrointestinal disorders. Neurogastroenterol Motil 2008;20 Suppl 1:130-8. [PMID: 18402650 DOI: 10.1111/j.1365-2982.2008.01093.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
218 Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008;103:1217-25. [PMID: 18477346 DOI: 10.1111/j.1572-0241.2008.01808.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
219 Skoog SM, Bharucha AE, Zinsmeister AR. Comparison of breath testing with fructose and high fructose corn syrups in health and IBS. Neurogastroenterol Motil 2008;20:505-11. [PMID: 18221251 DOI: 10.1111/j.1365-2982.2007.01074.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
220 Chassany O, Matuchansky C. Probiotics and the irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:616-7; author reply 617-8. [PMID: 18194493 DOI: 10.1111/j.1365-2036.2008.03617.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
221 Mayer EA, Bradesi S, Chang L, Spiegel BM, Bueller JA, Naliboff BD. Functional GI disorders: from animal models to drug development. Gut 2008;57:384-404. [PMID: 17965064 DOI: 10.1136/gut.2006.101675] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 7.9] [Reference Citation Analysis]
222 Castilloux J, Noble A, Faure C. Is visceral hypersensitivity correlated with symptom severity in children with functional gastrointestinal disorders? J Pediatr Gastroenterol Nutr 2008;46:272-8. [PMID: 18376243 DOI: 10.1097/MPG.0b013e31814b91e7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
223 Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr. 2008;152:685-689. [PMID: 18410774 DOI: 10.1016/j.jpeds.2007.10.012] [Cited by in Crossref: 119] [Cited by in F6Publishing: 88] [Article Influence: 7.9] [Reference Citation Analysis]
224 Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57. [PMID: 17919270 DOI: 10.1111/j.1365-2036.2007.03542.x] [Cited by in Crossref: 234] [Cited by in F6Publishing: 226] [Article Influence: 15.6] [Reference Citation Analysis]
225 Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008;53:108-15. [PMID: 17503182 DOI: 10.1007/s10620-007-9830-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 5.5] [Reference Citation Analysis]
226 Chang FY, Lu CL, Chen CY, Luo JC. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007;22:2266-72. [PMID: 17559369 DOI: 10.1111/j.1440-1746.2007.04895.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
227 Duracinsky M, Chassany O. Syndrome de l’intestin irritable : pourquoi est-il si difficile de trouver un traitement efficace ? Colon Rectum 2007;1:248-254. [DOI: 10.1007/s11725-007-0059-3] [Reference Citation Analysis]
228 Madsen LG, Hansen JM, Grønvold M, Bytzer P. The validity of a symptom diary in ratings of dyspepsia measured against a detailed interview: do patients and clinicians agree in their assessment of symptoms? Aliment Pharmacol Ther 2007;26:905-12. [PMID: 17767475 DOI: 10.1111/j.1365-2036.2007.03432.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
229 Labus JS. In search of mechanisms of change in treatment outcome research: mediators and moderators of psychological and pharmacological treatments for irritable bowel syndrome. Gastroenterology 2007;133:702-5. [PMID: 17681186 DOI: 10.1053/j.gastro.2007.06.052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
230 Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475-86. [PMID: 17635382 DOI: 10.1111/j.1365-2036.2007.03362.x] [Cited by in Crossref: 247] [Cited by in F6Publishing: 228] [Article Influence: 15.4] [Reference Citation Analysis]
231 Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102:1709-19. [PMID: 17509028 DOI: 10.1111/j.1572-0241.2007.01282.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 4.9] [Reference Citation Analysis]
232 Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Blanchard EB. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology 2007;133:433-44. [PMID: 17681164 DOI: 10.1053/j.gastro.2007.05.014] [Cited by in Crossref: 112] [Cited by in F6Publishing: 120] [Article Influence: 7.0] [Reference Citation Analysis]
233 Drossman D, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, Dalton CB, Leserman J, Patrick DL, Bangdiwala SI. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007;102:1442-53. [PMID: 17509027 DOI: 10.1111/j.1572-0241.2007.01283.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 5.4] [Reference Citation Analysis]
234 Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007;5:534-40. [PMID: 17428741 DOI: 10.1016/j.cgh.2007.03.004] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 4.4] [Reference Citation Analysis]
235 Chassany O, Bonaz B, Bruley DES Varannes S, Bueno L, Cargill G, Coffin B, Ducrotté P, Grangé V. Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2007;25:1115-23. [PMID: 17439513 DOI: 10.1111/j.1365-2036.2007.03296.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
236 Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007;50:428-41. [PMID: 17294322 DOI: 10.1007/s10350-006-0814-9] [Cited by in Crossref: 218] [Cited by in F6Publishing: 166] [Article Influence: 13.6] [Reference Citation Analysis]
237 Gawrońska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177-84. [PMID: 17229242 DOI: 10.1111/j.1365-2036.2006.03175.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 157] [Article Influence: 10.5] [Reference Citation Analysis]
238 Myllyluoma E, Kajander K, Saxelin M. Functional dairy products for gastrointestinal infections and dysfunction. Functional Dairy Products 2007. [DOI: 10.1533/9781845693107.1.63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
239 Fukudo S. Functional Gastrointestinal Disorders: Rome III Standard and Their Physiopathology. J Jpn Soc Intern Med 2007;96:1220-1227. [DOI: 10.2169/naika.96.1220] [Reference Citation Analysis]
240 Mangel AW, Fehnel S. Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al. Am J Gastroenterol 2006;101:2884-5; author reply 2885-7. [PMID: 17227528 DOI: 10.1111/j.1572-0241.2006.00867_1.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]